Your browser doesn't support javascript.
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Eyre, David W; Lumley, Sheila F; Wei, Jia; Cox, Stuart; James, Tim; Justice, Anita; Jesuthasan, Gerald; O'Donnell, Denise; Howarth, Alison; Hatch, Stephanie B; Marsden, Brian D; Jones, E Yvonne; Stuart, David I; Ebner, Daniel; Hoosdally, Sarah; Crook, Derrick W; Peto, Tim E A; Walker, Timothy M; Stoesser, Nicole E; Matthews, Philippa C; Pouwels, Koen B; Walker, A Sarah; Jeffery, Katie.
  • Eyre DW; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Nuffield Department of Population Health, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobi
  • Lumley SF; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health Engl
  • Wei J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Cox S; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • James T; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Justice A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Jesuthasan G; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • O'Donnell D; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Howarth A; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hatch SB; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Marsden BD; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Kennedy Institute of Rheumatology Research, University of Oxford, UK.
  • Jones EY; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Stuart DI; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Ebner D; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Target Discovery Institute, University of Oxford, Oxford, UK.
  • Hoosdally S; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health England, Oxford, UK; Nuffield Department of Medicine, University o
  • Crook DW; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health Engl
  • Peto TEA; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health Engl
  • Walker TM; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet nam.
  • Stoesser NE; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health Engl
  • Matthews PC; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health Engl
  • Pouwels KB; Nuffield Department of Population Health, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health England, Oxford, UK.
  • Walker AS; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in Partnership with Public Health England, Oxford, UK; Nuffield Department of Medicine, University o
  • Jeffery K; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Clin Microbiol Infect ; 27(10): 1516.e7-1516.e14, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1260697
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

OBJECTIVES:

We investigated determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike IgG responses in healthcare workers (HCWs) following one or two doses of Pfizer-BioNTech or Oxford-AstraZeneca vaccines.

METHODS:

HCWs participating in regular SARS-CoV-2 PCR and antibody testing were invited for serological testing prior to first and second vaccination, and 4 weeks post-vaccination if receiving a 12-week dosing interval. Quantitative post-vaccination anti-spike antibody responses were measured using the Abbott SARS-CoV-2 IgG II Quant assay (detection threshold ≥50 AU/mL). We used multivariable logistic regression to identify predictors of seropositivity and generalized additive models to track antibody responses over time.

RESULTS:

3570/3610 HCWs (98.9%) were seropositive >14 days post first vaccination and prior to second vaccination 2706/2720 (99.5%) were seropositive after the Pfizer-BioNTech and 864/890 (97.1%) following the Oxford-AstraZeneca vaccines. Previously infected and younger HCWs were more likely to test seropositive post first vaccination, with no evidence of differences by sex or ethnicity. All 470 HCWs tested >14 days after the second vaccination were seropositive. Quantitative antibody responses were higher after previous infection median (IQR) >21 days post first Pfizer-BioNTech 14 604 (7644-22 291) AU/mL versus 1028 (564-1985) AU/mL without prior infection (p < 0.001). Oxford-AstraZeneca vaccine recipients had lower readings post first dose than Pfizer-BioNTech recipients, with and without previous infection, 10 095 (5354-17 096) and 435 (203-962) AU/mL respectively (both p < 0.001 versus Pfizer-BioNTech). Antibody responses >21 days post second Pfizer vaccination in those not previously infected, 10 058 (6408-15 582) AU/mL, were similar to those after prior infection followed by one vaccine dose.

CONCLUSIONS:

SARS-CoV-2 vaccination leads to detectable anti-spike antibodies in nearly all adult HCWs. Whether differences in response impact vaccine efficacy needs further study.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article